Evaluation of sulfobutylether-ß-cyclodextrin (SBECD) exposure in a critically ill patient receiving intravenous posaconazole while undergoing continuous venovenous hemofiltration.
Antimicrob Agents Chemother. 2015 Aug 10;
Authors: Morris AA, Mueller SW, Rower JE, Washburn T, Kiser TH
We present a 31 year old female, status post allogeneic bone marrow transplantation who was started on intravenous posaconazole for pulmonary mycosis while undergoing CVVH. We performed steady-state pharmacokinetic evaluations for both posaconazole and sulfobutylether-ß-cyclodextrin (SBECD). SBECD was effectively removed by CVVH with observed exposure similar to patients with moderate renal impairment. Intravenous posaconazole at standard doses may be utilized in critically ill patients undergoing CVVH without significant risk of SBECD accumulation.
PMID: 26259790 [PubMed - as supplied by publisher]